

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

Brilliant Violet 510(TM) anti-mouse/human CD44

RRID:AB_2561391

Type: Antibody

Proper Citation

BioLegend Cat# 103043, RRID:AB_2561391

Antibody Information

URL: http://antibodyregistry.org/AB_2561391

Proper Citation: BioLegend Cat# 103043, RRID:AB_2561391

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2561391

Vendor: BioLegend

Catalog Number: 103043

Alternative Catalog Numbers: 103044

Record Creation Time: 20250820T053541+0000

Record Last Update: 20250820T215751+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 510(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mattavelli G, et al. (2025) A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. *Immunity*.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Marchingo JM, et al. (2025) PIM kinase control of CD8 T cell protein synthesis and cell trafficking. *eLife*, 13.

Huang SW, et al. (2025) Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. *eLife*, 13.

Miao N, et al. (2024) Tumor cell-intrinsic Piezo2 drives radioresistance by impairing CD8+ T cell stemness maintenance. *The Journal of experimental medicine*, 221(10).

Bejarano L, et al. (2024) Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. *Cancer cell*, 42(3), 378.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. *Cell metabolism*, 36(3), 630.

Canella A, et al. (2023) Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment. *Cell reports*, 42(8), 112891.

Santiago-Carvalho I, et al. (2023) T cell-specific P2RX7 favors lung parenchymal CD4+ T cell accumulation in response to severe lung infections. *Cell reports*, 42(11), 113448.

Prokhnevskaya N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. *Immunity*, 56(1), 107.

Wilfahrt D, et al. (2021) Histone deacetylase 3 represses cholesterol efflux during CD4+ T-cell activation. *eLife*, 10.

Jütte BB, et al. (2021) Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiency. *iScience*, 24(8), 102833.

León-Letelier RA, et al. (2020) Induction of Progenitor Exhausted Tissue-Resident Memory CD8⁺ T Cells Upon Salmonella Typhi Porins Adjuvant Immunization Correlates With Melanoma Control and Anti-PD-1 Immunotherapy Cooperation. *Frontiers in immunology*, 11, 583382.

Simula L, et al. (2018) Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. *Cell reports*, 25(11), 3059.